Comparison of two types of xenogeneic matrices to treat single gingival recessions: A randomized clinical trial.

BACKGROUND: Xenogeneic matrices (XMs) have been increasingly used for root coverage procedures. This study compared the use of two types of XM (collagen matrix [CM] and xenogeneic acellular dermal matrix [XDM]) associated with the coronally advanced flap technique (CAF) to treat single gingival recessions. METHODS: Seventy-five patients presenting single RT1 gingival recession were treated by CAF (control group, n = 25), CAF+CM (test group 1, n = 25), or CAF+XDM (test group 2, n = 25) and completed 6-month follow-up. Clinical, patient-centered, and esthetic assessments were performed and intra- and intergroup differences were analyzed. RESULTS: At 6 months, the mean recession reduction for CAF, CAF+CM, and CAF+XDM was 2.4 ± 0.8 mm, 2.4 ± 0.9 mm and 2.1 ± 0.8 mm, respectively (P > 0.05). The corresponding mean percentage of root coverage was 78.9% ± 26.2% for CAF, 78.0% ± 28.5% for CAF+CM, and 65.6% ± 26.9% for CAF+XDM (P > 0.05). Dentin hypersensitivity and esthetic conditions showed significantly improvements in all groups. Test groups presented significant gains in gingival thickness (GT; CAF+CM: 0.4 ± 0.3 mm; CAF+XDM: 0.4 ± 0.2 mm) compared to the control group (CAF: 0.0 ± 0.1 mm; P < 0.05). CONCLUSION: The CAF, CAF+CM, and CAF+XDM treatments each provided similar results in the treatment of single gingival recessions. The addition of either CM or XDM to CAF increases the GT.

Bilateral mandibular buccal bifurcation cyst: a case report emphasizing the role of imaging examination in the diagnosis.

A mandibular buccal bifurcation cyst is an inflammatory cyst that usually occurs on the buccal aspect of the permanent mandibular first molar of children. This lesion is diagnosed by an association of radiographic, clinical, and histological features. We report a bilateral case of mandibular buccal bifurcation cyst and discuss the main findings of this entity. A 7-year-old girl presented pain and delayed dental eruption in the posterior mandibular region. A cone beam computed tomography was performed and revealed hypodense lesions involving the crown and root of the mandibular first molars, with expansion of the buccal cortical and lingual tilting of the molar roots. A biopsy was carried out, and the common features of an inflammatory odontogenic cyst were histologically observed. The final diagnosis was bilateral mandibular buccal bifurcation cyst. Clinicians need to be aware of this diagnostic possibility in cases of mandibular cysts in children-especially when bilateral-to perform the correct treatment, which should not involve the extraction of the affected tooth.

Sitagliptin's effects on bone tissue and osseointegration in diabetic rats.

OBJECTIVE: To investigate the effects of sitagliptin, a dipeptidyl peptidase 4 inhibitor used to treat type II diabetes, on bone tissue and on implant osseointegration in diabetic rats. DESIGN: Thirty-two male rats were divided into four groups: 1) Diabetic animals (GD); 2) Diabetic animals that received sitagliptin (GDS); 3) Normoglycemic animals (GN); and 4) Normoglycemic animals that received sitagliptin (GNS). All animals received titanium implants in the right tibia. Sitagliptin or water were administered for 4 weeks. Glycemia, HOMA-IR, insulinemia, microtomographic parameters of the left tibia and implant bone area fraction occupancy (BAFO) of the right tibia were evaluated. RESULTS: The model used to induce diabetes led to hyperglycemia. However, HOMA-IR results showed no insulin resistance, and insulinemia was lower in diabetic animals, demonstrating the development of type I diabetes. Sitagliptin administration did not influence glycemic control. The diabetic animals showed a lower BAFO and bone volume fraction, as well as a lower trabecular number and thickness, revealing the deleterious effect of diabetes on bone metabolism and osseointegration. CONCLUSION: In this model, sitagliptin administration did not reverse the negative effects of type I diabetes on bone, suggesting that sitagliptin has no direct action on bone tissue and has no protective bone action in decompensated diabetic animals.

Bilateral mandibular buccal bifurcation cyst: a case report emphasizing the role of imaging examination in the diagnosis

A mandibular buccal bifurcation cyst is an inflammatory cyst that usually occurs on the buccal aspect of the permanent mandibular first molar of children. This lesion is diagnosed by an association of radiographic, clinical, and histological features. We report a bilateral case of mandibular buccal bifurcation cyst and discuss the main findings of this entity. A 7-year-old girl presented pain and delayed dental eruption in the posterior mandibular region. A cone beam computed tomography was performed and revealed hypodense lesions involving the crown and root of the mandibular first molars, with expansion of the buccal cortical and lingual tilting of the molar roots. A biopsy was carried out, and the common features of an inflammatory odontogenic cyst were histologically observed. The final diagnosis was bilateral mandibular buccal bifurcation cyst. Clinicians need to be aware of this diagnostic possibility in cases of mandibular cysts in children­especially when bilateral­to perform the correct treatment, which should not involve the extraction of the affected tooth.

Efeitos da sitagliptina no tecido ósseo em ratos diabéticos e não diabéticos / Effects of sitagliptin on bone tissue in diabetic and non-diabetic rats

A diabetes mellitus, doença caracterizada pelo aumento da glicemia no sangue, é um dos mais importantes problemas de saúde pública do mundo, com incidência crescente, sobretudo em países em desenvolvimento. Novas terapias medicamentosas para controlar os níveis de glicose no sangue têm sido desenvolvidas, entre elas, os inibidores da enzima dipeptidil peptidase-4 (DPP-4) como a sitagliptina. Pesquisas atuais mostram que este medicamento, além do controle da glicemia, contribui na estimulação da formação e inibição da reabsorção óssea e possui ação anti-inflamatória. O objetivo deste trabalho foi avaliar os efeitos da sitagliptina no tecido ósseo em ratos diabéticos e não diabéticos. Foram utilizados 38 ratos machos, divididos em 4 grupos: Grupo diabético tratado com sitagliptina (GDS- 10 mg/Kg/dia); Grupo diabético (GD); Grupo normoglicêmico tratado sitagliptina (GNS-10 mg/Kg/dia); Grupo normoglicêmico (GN). Para indução da diabetes os animais receberam solução 10% de frutose na água de beber por 14 dias, após o quê receberam 40 mg/Kg de estreptozotocina via intraperitoneal. Quatro semanas depois, avaliou-se a glicemia e iniciou-se o tratamento com sitagliptina nos grupos GDS e GNS, que continuou por mais 4 semanas, quando ocorreu a eutanásia. A glicemia e a resistência à insulina (HOMA-IR) foram avaliadas também no dia da eutanásia. As tíbias foram removidas e avaliadas a porcentagem de volume ósseo (BV/TV), espessura trabecular (Tb.Th), número de trabéculas (Tb.N) e a separação de trabéculas (Tb Sp) da metáfise tibiana por microtomografia computadorizada. Os dados foram submetidos à análise estatística, ao nível de 0,05. Os animais dos grupos GD e GDS apresentaram maior glicemia que os animais dos demais grupos, mas não houve diferença entre os grupos com relação aos dados de HOMA-IR, evidenciando a indução de diabetes do tipo I. Os animais diabéticos apresentaram menor BV/TV e Tb.N, e maior Tb.Sp. Não houve diferença com relação à Tb.Th. O modelo experimental foi eficaz para a indução da diabetes, mas o tratamento com sitagliptina não foi suficiente para reverter os efeitos da diabetes no tecido ósseo(AU)

Diabetes mellitus, a disease characterized by increased blood glucose levels, is one of the most important public health problems in the world, with a growing incidence, especially in developing countries. New drug therapies to control blood glucose levels have been developed, including dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin. Current research shows that this drug, in addition to glycemic control, contributes to stimulate the formation and inhibition of bone resorption and has an anti-inflammatory action. The aim of this study was to evaluate the effects of sitagliptin on bone tissue in diabetic and non-diabetic rats. Thirty-eight male rats were divided into four groups: Diabetic group treated with sitagliptin (GDS-10 mg / kg / day); Diabetic group (GD); normoglycemic group treated with sitagliptin (GNS-10 mg / kg / day); normoglycemic group (GN). For induction of diabetes the animals received 10% solution of fructose in the drinking water for 14 days, after which they received 40 mg / kg streptozotocin intraperitoneally. Four weeks later, glycemia was evaluated and sitagliptin treatment was started in the GDS and GNS groups, which continued for another 4 weeks, when euthanasia occurred. Blood glucose and insulin resistance (HOMA-IR) were also evaluated on the day of sacrifice. Bone volume (BV/TV), trabecular thickness (Tb.Th), number of trabeculae (Tb.N) and trabeculae separation (Tb.Sp) of the tibial metaphysis were evaluated by computerized microtomography. Data were submitted to statistical analysis at the 0.05 level. The animals of groups GD and GDS presented higher glycemia, but there was no difference regarding HOMA-IR, evidencing diabetes type I induction. The animals in which diabetes was induced presented lower BV/TV and Tb.N, and higher Tb.Sp. There was no difference among groups in TB.Th. The experimental model was sufficient for the induction of diabetes, but treatment with sitagliptin was not enough to reverse the effects of diabetes on bone tissue(AU)